CLINICAL TRIALS

If you would like your clinical trial listed on our website, please contact maryangela@gimotility-agmd.org to receive our Clinical Study Announcement Application.

RESEARCH MATCH

The Association of Gastrointestinal Motility Disorders is collaborating with ResearchMatch.org to share information about access to clinical trials and educate the public about gastrointestinal disorders.

You can listen to the presentation here, https://youtu.be/bhBdOHgJj7M. We encourage you to also check out their stories about research studies and clinical trial participation: https://medium.com/researchmatch/tagged/research.

We are grateful To ResearchMatch for the opportunity!

A Reandomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects with Idiopathic Gastroparesis

The purpose of the study is to evaluate the safety and efficacy of CIN-102 (duedomperidone) to relieve symptoms of idiopathic gastroparesis.

Sponsor: CinDome Pharma, Inc.

Condition: Idiopathic Gastroparesis

Treatment or Intervention: CIN-102 (15 mg or 10 mg) or Placebo taken twice daily by mouth for 12 weeks.

Phase of Trial: 2

Type of Study: Interventional

Inclusion Criteria: a. Age 18 or older b. Current diagnosis of gastroparesis c. Within the last 6 months, experienced gastrointestinal symptoms such as nausea or vomiting after eating, feeling too full after eating, bloating, and/or throat or stomach pain.

*Additional inclusion criteria apply

Exclusion Criteria:

a. Known primary cause of gastroparesis

b. Current diagnosis of Type 1 or 2 diabetes

c. Hospitalized for gastroparesis or malnutrition within 3 months prior to screening

*Additional exclusion criteria apply

Study Start Date: FPFV January 2025

PEDIATRIC FUNCTIONAL GASTROINTESTINAL DISORDER OR MOTILITY DISORDER

Body Surface Gastric Mapping in Patients with GI Symptoms

The purpose of this study is to learn more about a new device that measures stomach and bowel myoelectric (electricity produced by muscles) activity in children and young adults using body surface gastric mapping (BSGM). The BSGM device is FDA approved in adults but not children under 18.

We are looking to partner with patients who have a confirmed diagnosis of a Motility Disorder and/or Functional Gastrointestinal Disorder (FGID) or patients who are having motility tests/procedures performed for clinical care. We are also looking for healthy controls without any history of inflammatory disease or pyloric disorders. All study participants must be 8 – 25 years of age and have a body mass index (BMI) of less than 35.

Participation is completely voluntary, and subjects may withdraw at any time without affecting their care. Participants may receive compensation for their time.

If you are interested in participating in the study or want to learn more please contact our study team at BSGMstudy@chop.edu or 267-251-6768.

FECAL INCONTINENCE RESEARCH PROGRAM